Therefore, suppressing the expression and production of IL-31 in cellular processes will be beneficial for the treatment of chronic inflammatory diseases, including but not limited to atopic dermatitis, pruritus, inflammatory bowel diseases, and airway hypersensitivity. This evidence concerns the gene IL31 and atopic eczema.